TEVAR (Thoracic Endovascular Aortic Repair): Scoping Review with ☸️SAIMSARA
SAIMSARA Journal · 02.05.2026 · 1 (1)
DOI: 10.62487/saimsara045f98bf ↗Kurz gefasst
Scoping Review in der Zeitschrift SAIMSARA Journal, online erschienen am 02.05.2026. Die Arbeit nennt 244 Literaturangaben.
Abstract (Originalsprache)
The aim of this scoping review is to synthesize the current evidence regarding the clinical outcomes, technical advancements, and complication profiles of thoracic endovascular aortic repair (TEVAR) across diverse aortic substrates, with a focus on optimizing patient selection and procedural timing. The review utilises 2530 original studies with 3319112 total participants (topic deduplicated ΣN). The mapped evidence supports TEVAR as the dominant contemporary strategy for descending thoracic aortic pathology, with consistent signals of lower perioperative mortality compared with open surgical repair (in-hospital mortality 5.9% versus 15.3% in acute type B aortic dissection) and improved 5-year survival relative to medical therapy (91.9% versus 82.2% in acute uncomplicated type B aortic dissection). Across the dominant research topics, TEVAR was associated with favorable false lumen thrombosis (up to 72.1% versus 20.0% with medical therapy) and superior aortic remodeling, particularly when performed in the subacute window, while controlled device-trial data also indicated lower aneurysm-related mortality for descending thoracic aneurysms in anatomically suitable patients. Recurrent signals across topics highlight that left subclavian artery management, proximal landing zone selection, oversizing strategy, and frailty status modulate risk of stroke, spinal cord ischemia, distal stent graft-induced new entry, and retrograde type A dissection, indicating that procedural success is anatomy- and patient-specific rather than uniformly favorable. Clinically, this evidence map supports a tailored approach combining subacute timing when feasible, selective left subclavian artery revascularization, conservative oversizing, and lifelong imaging surveillance for endoleak and aneurysmal progression. The most prominent uncertainty concerns preemptive TEVAR in uncomplicated type B aortic dissection, where randomized and observational data remain discordant on long-term mortality benefit. Future research should prioritize adequately powered randomized trials in high-risk uncomplicated type B aortic dissection, standardized definitions for distal stent graft-induced new entry and post-implantation syndrome, and prospective evaluation of patient-specific computational and digital twin planning to refine device selection and landing-zone strategy.
Zitieren
APA
(2026). TEVAR (Thoracic Endovascular Aortic Repair): Scoping Review with ☸️SAIMSARA. SAIMSARA Journal, 1(1). https://doi.org/10.62487/saimsara045f98bf
Vancouver
TEVAR (Thoracic Endovascular Aortic Repair): Scoping Review with ☸️SAIMSARA. SAIMSARA Journal. 2026;1(1). doi:10.62487/saimsara045f98bf
BibTeX
@article{euvimed2026,
title = {TEVAR (Thoracic Endovascular Aortic Repair): Scoping Review with ☸️SAIMSARA},
journal = {SAIMSARA Journal},
year = {2026},
volume = {1},
number = {1},
doi = {10.62487/saimsara045f98bf}
}
EUVIMED